PMID- 23369368
OWN - NLM
STAT- MEDLINE
DCOM- 20130813
LR  - 20181202
IS  - 1879-114X (Electronic)
IS  - 0149-2918 (Linking)
VI  - 35
IP  - 2
DP  - 2013 Feb
TI  - Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from 
      phase II and III trials.
PG  - 190-7
LID - S0149-2918(12)00734-5 [pii]
LID - 10.1016/j.clinthera.2012.12.017 [doi]
AB  - BACKGROUND: Telaprevir and boceprevir are protease inhibitors now added to 
      therapy for patients with chronic hepatitis C virus (HCV) genotype 1 infection 
      who either are treatment naive or have a history of relapse or recurrence 
      following a previous course of treatment with pegylated interferon + ribavirin 
      (Peg-IFN + RBV). Because these agents are fairly new to the market, providers may 
      have limited experience with them in the management of chronic HCV. OBJECTIVE: 
      This meta-analysis compared 24- and 48-week sustained viral responses (SVR) and 
      drug-related adverse events (AEs) between telaprevir and boceprevir 
      triple-therapy regimens in the treatment of chronic HCV infection. METHODS: 
      MEDLINE, EMBASE, and Cochrane databases were searched for articles published from 
      January 1995 to October 2012 on randomized controlled trials that reported SVR at 
      >/=24 weeks in patients with HCV receiving triple-therapy regimens that included 
      telaprevir or boceprevir or placebo + pegylated interferon + ribavirin (Peg-IFN + 
      RBV). Pooled odds ratios (ORs) were calculated and used to compare SVR at 24 and 
      48 weeks. Secondary end points included common drug-related AEs and treatment 
      discontinuations. RESULTS: Eight studies were included in this meta-analysis (N = 
      4144 treatment-naive and treatment-experienced patients). With telaprevir, the 
      ORs (95% CI) for SVR at 24 weeks in treatment-naive and treatment-experienced 
      patients were 3.31 (2.27-4.82; P < 0.0001) and 4.21 (1.83-9.72; P = 0.001), 
      respectively. Telaprevir triple therapy did not result in more drug-related 
      discontinuations but did cause additional rash, pruritis, and anemia. With 
      boceprevir, the ORs (95% CI) were improved in both treatment-naive and treatment 
      experienced patients (3.55 [2.66-4.56; P < 0.0001] and 7.34 [3.92-13.9; P < 
      0.0001]), but with more treatment-related anemia and dysgeusia. CONCLUSIONS: 
      Based on the findings from this meta-analysis, telaprevir or boceprevir combined 
      with Peg-IFN + RBV had favorable short-term data on SVR while resulting in more 
      drug-related AEs. Extended follow-up is required to determine whether these 
      agents offer a reduction in the risk for chronic hepatitis C genotype 1-related 
      mortality and/or hospitalization.
CI  - Copyright (c) 2013 Elsevier HS Journals, Inc. All rights reserved.
FAU - Sitole, Mugdha
AU  - Sitole M
AD  - Massachusetts College of Pharmacy & Health Sciences, Worcester, MA 01608, USA. 
      mugdha.sitole@mcphs.edu
FAU - Silva, Matthew
AU  - Silva M
FAU - Spooner, Linda
AU  - Spooner L
FAU - Comee, Morgan K
AU  - Comee MK
FAU - Malloy, Michael
AU  - Malloy M
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20130129
PL  - United States
TA  - Clin Ther
JT  - Clinical therapeutics
JID - 7706726
RN  - 0 (Interferon-alpha)
RN  - 0 (Oligopeptides)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 655M5O3W0U (telaprevir)
RN  - 89BT58KELH 
      (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
RN  - 9DLQ4CIU6V (Proline)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Drug Therapy, Combination
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Oligopeptides/administration & dosage/adverse effects/*therapeutic use
MH  - Polyethylene Glycols/therapeutic use
MH  - Proline/administration & dosage/adverse effects/*analogs & 
      derivatives/therapeutic use
MH  - Protease Inhibitors/administration & dosage/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/therapeutic use
EDAT- 2013/02/02 06:00
MHDA- 2013/08/14 06:00
CRDT- 2013/02/02 06:00
PHST- 2012/11/08 00:00 [received]
PHST- 2012/12/22 00:00 [revised]
PHST- 2012/12/28 00:00 [accepted]
PHST- 2013/02/02 06:00 [entrez]
PHST- 2013/02/02 06:00 [pubmed]
PHST- 2013/08/14 06:00 [medline]
AID - S0149-2918(12)00734-5 [pii]
AID - 10.1016/j.clinthera.2012.12.017 [doi]
PST - ppublish
SO  - Clin Ther. 2013 Feb;35(2):190-7. doi: 10.1016/j.clinthera.2012.12.017. Epub 2013 
      Jan 29.